Overview

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Phase:

PHASE2

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Cyclophosphamide
Doxorubicin
Filgrastim
pegfilgrastim
polatuzumab vedotin
Prednisone